Real-world use of polatuzumab vedotin combined with bendamustine and rituximab for patients with relapsed or refractory large B-cell lymphoma
Changgon Kim, Sang Eun Yoon, Hyun-Young Kim, Duck Cho, Junhun Cho, Won Seog Kim, Seok Jin Kim
Korean J Intern Med. 2026;41(2):296-306. Published online 2026 Mar 1 DOI: https://doi.org/10.3904/kjim.2025.282
Citations to this article as recorded by 
A bridge, not a destination: clarifying the role of polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory diffuse large B-cell lymphoma
Ho-Young Yhim
The Korean Journal of Internal Medicine.2026; 41(2): 183. CrossRef